Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome
- PMID: 24764580
- PMCID: PMC4000890
- DOI: 10.1158/2326-6066.CIR-13-0136
Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome
Abstract
The presence of regulatory T cells (Treg) in solid tumors is known to play a role in patient survival in ovarian cancer and other malignancies. We assessed inherited genetic variations via 749 tag single-nucleotide polymorphisms (SNP) in 25 Treg-associated genes (CD28, CTLA4, FOXP3, IDO1, IL10, IL10RA, IL15, 1L17RA, IL23A, IL23R, IL2RA, IL6, IL6R, IL8, LGALS1, LGALS9, MAP3K8, STAT5A, STAT5B, TGFB1, TGFB2, TGFB3, TGFBR1, TGRBR2, and TGFBR3) in relation to ovarian cancer survival. We analyzed genotype and overall survival in 10,084 women with invasive epithelial ovarian cancer, including 5,248 high-grade serous, 1,452 endometrioid, 795 clear cell, and 661 mucinous carcinoma cases of European descent across 28 studies from the Ovarian Cancer Association Consortium (OCAC). The strongest associations were found for endometrioid carcinoma and IL2RA SNPs rs11256497 [HR, 1.42; 95% confidence interval (CI), 1.22-1.64; P = 5.7 × 10(-6)], rs791587 (HR, 1.36; 95% CI, 1.17-1.57; P = 6.2 × 10(-5)), rs2476491 (HR, = 1.40; 95% CI, 1.19-1.64; P = 5.6 × 10(-5)), and rs10795763 (HR, 1.35; 95% CI, 1.17-1.57; P = 7.9 × 10(-5)), and for clear cell carcinoma and CTLA4 SNP rs231775 (HR, 0.67; 95% CI, 0.54-0.82; P = 9.3 × 10(-5)) after adjustment for age, study site, population stratification, stage, grade, and oral contraceptive use. The rs231775 allele associated with improved survival in our study also results in an amino acid change in CTLA4 and previously has been reported to be associated with autoimmune conditions. Thus, we found evidence that SNPs in genes related to Tregs seem to play a role in ovarian cancer survival, particularly in patients with clear cell and endometrioid epithelial ovarian cancer.
Conflict of interest statement
Conflict of interest: B Charbonneau was an employee of Mayo Clinic at the time this manuscript was drafted and is currently an employee of and owns stock in Eli Lilly and Company.
Figures



Similar articles
-
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.Lancet Oncol. 2013 Aug;14(9):853-62. doi: 10.1016/S1470-2045(13)70253-5. Epub 2013 Jul 9. Lancet Oncol. 2013. PMID: 23845225 Free PMC article.
-
Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer.Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1421-7. doi: 10.1158/1055-9965.EPI-13-0962. Epub 2014 Apr 16. Cancer Epidemiol Biomarkers Prev. 2014. PMID: 24740199 Free PMC article.
-
Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis.PLoS Med. 2019 Aug 7;16(8):e1002893. doi: 10.1371/journal.pmed.1002893. eCollection 2019 Aug. PLoS Med. 2019. PMID: 31390370 Free PMC article.
-
Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.Int J Gynecol Cancer. 2010 Aug;20(6):945-52. doi: 10.1111/IGC.0b013e3181dd0110. Int J Gynecol Cancer. 2010. PMID: 20683400 Review.
-
Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas.JAMA Netw Open. 2023 Jun 1;6(6):e2318602. doi: 10.1001/jamanetworkopen.2023.18602. JAMA Netw Open. 2023. PMID: 37326992 Free PMC article.
Cited by
-
Targeted immune therapy of ovarian cancer.Cancer Metastasis Rev. 2015 Mar;34(1):53-74. doi: 10.1007/s10555-014-9540-2. Cancer Metastasis Rev. 2015. Retraction in: Cancer Metastasis Rev. 2016 Sep;35(3):489. doi: 10.1007/s10555-016-9627-z. PMID: 25544369 Free PMC article. Retracted. Review.
-
Transcription factor FOXP3 gene variants affect epithelial ovarian carcinoma in the Han Chinese population.Int J Clin Exp Pathol. 2018 Mar 1;11(3):1684-1693. eCollection 2018. Int J Clin Exp Pathol. 2018. PMID: 31938270 Free PMC article.
-
Evaluation of PTEN and CD4+FOXP3+ T cell expressions as diagnostic and predictive factors in endometrial cancer: A case control study.Medicine (Baltimore). 2019 Jul;98(30):e16345. doi: 10.1097/MD.0000000000016345. Medicine (Baltimore). 2019. PMID: 31348233 Free PMC article.
-
Association of CTLA-4 polymorphisms with hematologic malignancy susceptibility: a meta-analysis.Front Oncol. 2024 Oct 11;14:1467740. doi: 10.3389/fonc.2024.1467740. eCollection 2024. Front Oncol. 2024. PMID: 39464701 Free PMC article.
-
Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer.Cancer Immunol Immunother. 2015 Dec;64(12):1495-504. doi: 10.1007/s00262-015-1753-x. Epub 2015 Aug 23. Cancer Immunol Immunother. 2015. PMID: 26298430 Free PMC article.
References
-
- Zhao X, Wei YQ, Peng ZL. Induction of T cell responses against autologous ovarian tumors with whole tumor cell lysate-pulsed dendritic cells. Immunol Invest. 2001;30:33–45. - PubMed
-
- Yigit R, Massuger LF, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol. 2010;117:366–372. - PubMed
-
- Bilate AM, Lafaille JJ. Induced CD4+Foxp3+ regulatory T cells in immune tolerance. Annu Rev Immunol. 2012;30:733–758. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R03-CA115195/CA/NCI NIH HHS/United States
- R01-CA61107/CA/NCI NIH HHS/United States
- R01-CA092044/CA/NCI NIH HHS/United States
- U01 CA069417/CA/NCI NIH HHS/United States
- R01 CA050385/CA/NCI NIH HHS/United States
- R25 CA092049/CA/NCI NIH HHS/United States
- R01-CA067262/CA/NCI NIH HHS/United States
- N01 PC067010/PC/NCI NIH HHS/United States
- C490/A6187/CRUK_/Cancer Research UK/United Kingdom
- P01-CA017054/CA/NCI NIH HHS/United States
- C536/A13086/CRUK_/Cancer Research UK/United Kingdom
- P30 CA016056/CA/NCI NIH HHS/United States
- R01 CA087538/CA/NCI NIH HHS/United States
- R01 CA136924/CA/NCI NIH HHS/United States
- K22-CA138563/CA/NCI NIH HHS/United States
- R01 CA067262/CA/NCI NIH HHS/United States
- R01 CA106414/CA/NCI NIH HHS/United States
- P30 CA072720/CA/NCI NIH HHS/United States
- C490/A10119/CRUK_/Cancer Research UK/United Kingdom
- C536/A6689/CRUK_/Cancer Research UK/United Kingdom
- P30 CA168524/CA/NCI NIH HHS/United States
- 1 U19-CA148537/CA/NCI NIH HHS/United States
- N01-CN55424/CN/NCI NIH HHS/United States
- R01-CA054419/CA/NCI NIH HHS/United States
- R37-CA070867/CA/NCI NIH HHS/United States
- R03-CA113148/CA/NCI NIH HHS/United States
- R03 CA113148/CA/NCI NIH HHS/United States
- R01 CA058598/CA/NCI NIH HHS/United States
- R37 CA070867/CA/NCI NIH HHS/United States
- R01-CA112523/CA/NCI NIH HHS/United States
- R01-CA049449/CA/NCI NIH HHS/United States
- R01-CA080742/CA/NCI NIH HHS/United States
- K22 CA138563/CA/NCI NIH HHS/United States
- N01-PC067010/PC/NCI NIH HHS/United States
- R01-CA106414/CA/NCI NIH HHS/United States
- R01 CA058860/CA/NCI NIH HHS/United States
- C12292/A11174/CRUK_/Cancer Research UK/United Kingdom
- P20 GM103418/GM/NIGMS NIH HHS/United States
- R01 CA080742/CA/NCI NIH HHS/United States
- P30-CA072720/CA/NCI NIH HHS/United States
- R01-CA126841/CA/NCI NIH HHS/United States
- R01-CA058598/CA/NCI NIH HHS/United States
- R01 CA074850/CA/NCI NIH HHS/United States
- R25 CA92049/CA/NCI NIH HHS/United States
- R01-CA122443/CA/NCI NIH HHS/United States
- C5047/A10692/CRUK_/Cancer Research UK/United Kingdom
- K07 CA092044/CA/NCI NIH HHS/United States
- R01-CA087538/CA/NCI NIH HHS/United States
- R01-CA014089/CA/NCI NIH HHS/United States
- P50 CA105009/CA/NCI NIH HHS/United States
- N01 PC035137/CA/NCI NIH HHS/United States
- R01-CA074850/CA/NCI NIH HHS/United States
- P20-GM103418/GM/NIGMS NIH HHS/United States
- C490/A10124/CRUK_/Cancer Research UK/United Kingdom
- C5047/A8384/CRUK_/Cancer Research UK/United Kingdom
- R01 CA128978/CA/NCI NIH HHS/United States
- R01-CA061132/CA/NCI NIH HHS/United States
- C1287/A 10710/CRUK_/Cancer Research UK/United Kingdom
- R01-CA064277/CA/NCI NIH HHS/United States
- P30 CA076292/CA/NCI NIH HHS/United States
- R01 CA064277/CA/NCI NIH HHS/United States
- R01-CA050385/CA/NCI NIH HHS/United States
- P30 CA014089/CA/NCI NIH HHS/United States
- U19 CA148537/CA/NCI NIH HHS/United States
- MOP-86727/CAPMC/ CIHR/Canada
- P50-CA105009/CA/NCI NIH HHS/United States
- R01 CA083918/CA/NCI NIH HHS/United States
- U01-CA069417/CA/NCI NIH HHS/United States
- R01-CA136924/CA/NCI NIH HHS/United States
- R03 CA115195/CA/NCI NIH HHS/United States
- U01-CA071966/CA/NCI NIH HHS/United States
- R01-CA017054/CA/NCI NIH HHS/United States
- R01 CA054419/CA/NCI NIH HHS/United States
- R01 CA122443/CA/NCI NIH HHS/United States
- P30 CA015083/CA/NCI NIH HHS/United States
- C5047/A15007/CRUK_/Cancer Research UK/United Kingdom
- R01-CA016056/CA/NCI NIH HHS/United States
- R21-GM86689/GM/NIGMS NIH HHS/United States
- R01 CA076016/CA/NCI NIH HHS/United States
- R01-CA083918/CA/NCI NIH HHS/United States
- ImNIH/Intramural NIH HHS/United States
- K07 CA143047/CA/NCI NIH HHS/United States
- K07-CA143047/CA/NCI NIH HHS/United States
- R01 CA087696/CA/NCI NIH HHS/United States
- R01-CA149429/CA/NCI NIH HHS/United States
- A6187/CRUK_/Cancer Research UK/United Kingdom
- U19 CA148112/CA/NCI NIH HHS/United States
- R01 CA149429/CA/NCI NIH HHS/United States
- P30-CA168524/CA/NCI NIH HHS/United States
- R01-CA071766/CA/NCI NIH HHS/United States
- P01 CA017054/CA/NCI NIH HHS/United States
- P01-CA087696/CA/NCI NIH HHS/United States
- 13086/CRUK_/Cancer Research UK/United Kingdom
- N01 CN025403/CA/NCI NIH HHS/United States
- R01-CA128978/CA/NCI NIH HHS/United States
- R21 GM086689/GM/NIGMS NIH HHS/United States
- R01-CA114343/CA/NCI NIH HHS/United States
- R01 CA049449/CA/NCI NIH HHS/United States
- R01-CA076016/CA/NCI NIH HHS/United States
- R37-CA70867/CA/NCI NIH HHS/United States
- K07-CA095666/CA/NCI NIH HHS/United States
- R01 CA063682/CA/NCI NIH HHS/United States
- R01-CA061107/CA/NCI NIH HHS/United States
- P50-CA136393/CA/NCI NIH HHS/United States
- UM1 CA182910/CA/NCI NIH HHS/United States
- K07 CA095666/CA/NCI NIH HHS/United States
- C1287/A10118/CRUK_/Cancer Research UK/United Kingdom
- N01-PC035137/PC/NCI NIH HHS/United States
- R01 CA112523/CA/NCI NIH HHS/United States
- P50 CA136393/CA/NCI NIH HHS/United States
- R01 CA126841/CA/NCI NIH HHS/United States
- 15960/CRUK_/Cancer Research UK/United Kingdom
- P30-CA15083/CA/NCI NIH HHS/United States
- R01 CA114343/CA/NCI NIH HHS/United States
- R01-CA058860/CA/NCI NIH HHS/United States
- R01-CA080978/CA/NCI NIH HHS/United States
- 16561/CRUK_/Cancer Research UK/United Kingdom
- 10124/CRUK_/Cancer Research UK/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous